Lycernuic acid A is primarily studied for its potential anti-inflammatory and immunomodulatory properties. It has shown inhibitory activity against key inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2), making it a candidate for development in treatments targeting chronic inflammatory diseases. Research also indicates that it may suppress the expression of pro-inflammatory cytokines, including TNF-α and IL-6, in cellular models, suggesting utility in autoimmune conditions or neuroinflammatory disorders. Additionally, preliminary studies highlight its role in inducing apoptosis in certain cancer cell lines, pointing to possible applications in oncology, particularly as an adjuvant therapy. Due to its natural origin and observed bioactivity, it is being explored as a lead compound for novel pharmaceuticals in inflammation and cancer-related research.